GLP1R and Insulin resistance: Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA in 2022, has shown significant improvements in glycemic control and weight reduction without increasing hypoglycemia risk, further improving insulin resistance in T2D patients [188].